Personalis expands Tempus AI strategic collaboration

Personalis (PSNL) announced an expansion and extension of its strategic collaboration with Tempus AI (TEM), adding a new indication, colorectal cancer, to the existing, exclusive commercialization agreement. The update means Personalis and Tempus will now work to bring to market the NeXT Personal ultra-sensitive, tumor-informed minimal residual disease test to detect cancer recurrence in four areas: breast, lung and colorectal cancers, and solid tumor immunotherapy monitoring. The addition of CRC follows the presentation of compelling interim analysis results from the VICTORI study at the 2025 American Association for Cancer Research (AACR) Annual Meeting, which demonstrated strong performance of NeXT Personal for detecting early signs of residual or recurrent CRC. Personalis has amended its agreement with Tempus to further accelerate the adoption of NeXT Personal. The updated terms will: Expand the collaboration by adding CRC as the fourth indication for which Tempus will serve as Personalis’ exclusive commercial partner; Extend the term of the initial agreement to November 2029, and; Lengthen the period of Tempus’ exclusivity for all four indications through 2028.